Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586172 | 0.93 | PTGS2 (0.35) | CPS1PTGS2CAMKK1CAMKK2ACACB | |
| SCHEMBL12719389 | 0.91 | ACACB (0.33) | ACACBFFAR4NAAAFFAR1CRBN | |
| SCHEMBL12719399 | 0.91 | CRBN (0.34) | ACACBMEN1KMT2AFFAR4NAAA | |
| SCHEMBL12823935 | 0.90 | TYR (0.34) | NAAAAPP | |
| SCHEMBL14766831 | 0.90 | FFAR4 (0.42) | CPS1CAMKK1CAMKK2FFAR4NAAA | |
| SCHEMBL12822684 | 0.87 | ACACB (0.33) | PTGS2CAMKK1CAMKK2ACACBMEN1 | |
| SCHEMBL14767265 | 0.87 | FFAR4 (0.44) | CPS1CAMKK1CAMKK2FFAR4NAAA | |
| SCHEMBL12741452 | 0.87 | CAMKK1 (0.39) | CPS1CAMKK1CAMKK2FFAR4NAAA | |
| SCHEMBL12741476 | 0.87 | CAMKK1 (0.39) | CPS1CAMKK1CAMKK2FFAR4NAAA | |
| SCHEMBL12719765 | 0.87 | NAAA (0.45) | CPS1CAMKK1CAMKK2FFAR4NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CPS1 4819/4885PTGS2 3919/4885CAMKK1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.